Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Progression-Free Survival

Known as: Progression Free Survival, PFS, Progression-Free Survivals 
The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
BACKGROUND In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 3
Review
2011
Review
2011
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more… Expand
  • table 1
  • figure 3
  • table 2
Highly Cited
2009
Highly Cited
2009
BACKGROUND Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2008
Highly Cited
2008
PURPOSE As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
2006
Highly Cited
2006
Purpose: We reported previously that ≥5 circulating tumor cells (CTC) in 7.5 mL blood at baseline and at first follow-up in 177… Expand
  • table 2
  • figure 2
  • table 3
  • figure 3
Highly Cited
2006
Highly Cited
2006
Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis. This investigation prospectively assessed… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Highly Cited
2004
Highly Cited
2004
BACKGROUND We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
2004
Highly Cited
2004
BACKGROUND Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency… Expand
  • figure 1
Highly Cited
2004
Highly Cited
2004
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2003
Highly Cited
2003
BACKGROUND Although tumor-infiltrating T cells have been documented in ovarian carcinoma, a clear association with clinical… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3